Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan

Jpn J Clin Oncol. 2014 Oct;44(10):969-81. doi: 10.1093/jjco/hyu104. Epub 2014 Aug 6.

Abstract

Objective: The objective of the present study was to investigate the trends over time in the initial treatment of prostate cancer in Japan.

Methods: A total of 8291 patients with newly diagnosed prostate cancer whose treatment started in 2010 were registered in a multi-institutional observational study undertaken nationwide across Japan by the Japan Prostate Cancer Study Group. Each patient's background characteristics and initial treatment were recorded.

Results: The median age at diagnosis was 71 years. The proportion of T1c disease was 40.5% and that of M1 disease was 10.4%. The prostate-specific antigen level was <10 ng/ml in 52.0% of the patients. High-, intermediate- and low-risk patients as determined by D'Amico's classification system made up 19.3, 29.8 and 25.9% of the cases, respectively. The initial treatment was androgen depletion therapy in 40.2%, radical prostatectomy in 32.0% (17.3% of these involved laparoscopic prostatectomy), radiation in 21.0% (46.4% of these involved brachytherapy). In cases of organ-confined disease, radical prostatectomy was selected in 39.5%, androgen depletion therapy in 28.0% and radiation in 23.9%. In D'Amico's low-risk group, the proportion treated with radiation was nearly equal to that treated with radical prostatectomy (30.2 and 32.7%, respectively); 73.2% of the radiation treatments involved brachytherapy.

Conclusion: Compared with previous Japanese studies, radiation use was increased by ∼10%. This increased proportion of radiation use was a typical trend in initial therapy for newly diagnosed prostate cancer cases in Japan. Although androgen depletion therapy use was decreased, it was selected in a high proportion of the patients irrespective of the disease stage.

Keywords: J-CaP; androgen depletion therapy; prostate cancer; prostatectomy; radiation.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use*
  • Biomarkers, Tumor / blood
  • Brachytherapy*
  • Combined Modality Therapy
  • Humans
  • Japan
  • Male
  • Prostate-Specific Antigen / blood
  • Prostatectomy*
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / radiotherapy
  • Prostatic Neoplasms / surgery
  • Prostatic Neoplasms / therapy*

Substances

  • Androgen Antagonists
  • Biomarkers, Tumor
  • Prostate-Specific Antigen